Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti-VEGF

Table 1

Baseline demographics and ocular characteristics.

Characteristics	Mean ± SD or number of cases
Total number of eyes (n)	79
Age (range, years)	71 (range: 44–89)
Sex (male/female)	53/26
Eye treated (right/left)	38/41
Lens status	77 pseudophakic
Mean IVI received by N eyes	11.1 ± 4.7
Time to all injections (days)	913 ± 454.1
Total IVI count (n)	876
Ranibizumab	467
Aflibercept	391
Bevacizumab	19
IVTA	4
BRVA (logMAR)	0.55
CMT (μm)	474.4
MMT (μm)	496.3

Two cases were awaiting cataract surgery at baseline; four cases were excluded from the current analysis. BRVA: best-recorded visual acuity; CMT: central macular thickness; IVI: intravitreal injection; IVTA: intravitreal triamcinolone acetonide; MMT: maximal macular thickness; SD: standard deviation; VEGF: vascular endothelial growth factor.